+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Drug Addiction - Pipeline Review, H2 2020

  • ID: 5146927
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 216 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aelis Farma SAS
  • BioCorRx Inc
  • Curemark LLC
  • F. Hoffmann-La Roche Ltd
  • MElkin Pharmaceuticals
  • Orexigen Therapeutics Inc
  • MORE
Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H2 2020, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 9, 12, 33, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 3 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aelis Farma SAS
  • BioCorRx Inc
  • Curemark LLC
  • F. Hoffmann-La Roche Ltd
  • MElkin Pharmaceuticals
  • Orexigen Therapeutics Inc
  • MORE
Introduction
  • Drug Addiction - Overview
  • Drug Addiction - Therapeutics Development
Drug Addiction - Therapeutics Assessment

Drug Addiction - Companies Involved in Therapeutics Development

Drug Addiction - Drug Profiles

Drug Addiction - Dormant Projects
  • Drug Addiction - Discontinued Products
  • Drug Addiction - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Drug Addiction, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Drug Addiction - Pipeline by Adjuvance Technologies Inc, H2 2020
  • Drug Addiction - Pipeline by Aelis Farma SAS, H2 2020
  • Drug Addiction - Pipeline by Allaysis LLC, H2 2020
  • Drug Addiction - Pipeline by Amygdala Neurosciences Inc, H2 2020
  • Drug Addiction - Dormant Projects, H2 2020
  • Drug Addiction - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Drug Addiction, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • Adjuvance Technologies Inc
  • Aelis Farma SAS
  • Allaysis LLC
  • Amygdala Neurosciences Inc
  • Aphios Corp
  • Assertio Therapeutics Inc
  • Astellas Pharma Inc
  • Astraea Therapeutics LLC
  • BioCorRx Inc
  • Camino Pharma LLC
  • Cerevel Therapeutics LLC
  • Charleston Laboratories Inc
  • Chiesi Farmaceutici SpA
  • Chiromics LLC
  • Consegna Pharma Inc
  • Curemark LLC
  • D&A Pharma SAS
  • Daya Drug Discoveries Inc
  • DD Therapeutics LLC
  • Denovo Biopharma LLC
  • Elysium Therapeutics Inc
  • Embera NeuroTherapeutics Inc
  • EncepHeal Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Foresee Pharmaceuticals Co Ltd
  • Hua Medicine Shanghai Ltd
  • IMV Inc
  • InterveXion Therapeutics LLC
  • Intra-Cellular Therapies Inc
  • Kdac Therapeutics Inc
  • KemPharm Inc
  • Kinoxis Therapeutics Pty Ltd
  • Kyorin Pharmaceutical Co Ltd
  • MAKScientific LLC
  • MElkin Pharmaceuticals
  • Mind Medicine Inc
  • Mu Therapeutics Inc
  • NLS Pharma Group
  • Novartis AG
  • Omeros Corp
  • Orexigen Therapeutics Inc
  • Ovid Therapeutics Inc
  • P2D Inc
  • Paion AG
  • Protagenic Therapeutics Inc
  • Saniona AB
  • Sen-Jam Pharmaceutical LLC
  • Seropeutics LLC
  • Sosei Heptares
  • SpringWorks Therapeutics Inc
  • Tonix Pharmaceuticals Holding Corp
  • Trevena Inc
  • Vallon Pharmaceuticals Inc
  • Zelira Therapeutics Ltd
Note: Product cover images may vary from those shown
Adroll
adroll